DelveInsight’s ‘Chronic kidney disease (CKD)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Chronic kidney disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
Chronic Kidney Disease (CKD) Understanding
Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months to years. The initial symptoms include leg swelling, feeling tired, vomiting, loss of appetite, and confusion; complications in CKD involve anemia, bine disease, high blood pressure and increased risk of heart disease. Anemia is common and is especially prevalent in those requiring hemodialysis. It is multifactorial in cause, but includes increased inflammation, reduction in erythropoietin, and hyperuricemia leading to bone marrow suppression.
Chronic kidney disease Epidemiology Perspective by DelveInsight
The Chronic kidney disease (CKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Chronic kidney disease are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Chronic kidney disease Detailed Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed Prevalent cases of CKD, Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD) scenario of Chronic kidney disease (CKD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.
The DelveInsight CKD report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Scope of the Report
• The report covers detailed overview of Chronic kidney disease explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Chronic Kidney Disease (CKD) Report and Model provide an overview of the risk factors and global trends of CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides the insight about the historical and forecasted patient pool of Chronic kidney disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by Diagnosed Prevalent cases of CKD, Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD in 7MM
• 11 Years Forecast
• 7MM Coverage
• Total Diagnosed Prevalent Cases of Chronic Kidney Disease
• Prevalent Cases according to segmentation: Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acute Lymphoblastic Leukemia?
• What are the key findings pertaining to the Chronic Kidney Disease epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Chronic Kidney Disease across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What is the disease risk, burden and unmet needs of the Chronic Kidney Disease?
• What are the current available treatments of Chronic Kidney Disease?
Reasons to buy
The Chronic Kidney Disease Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Chronic Kidney Disease market
• Quantify patient populations in the global Chronic Kidney Disease market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chronic Kidney Disease therapeutics in each of the markets covered
• Understand the magnitude of Chronic Kidney Disease population by its severity
• The Chronic Kidney Disease epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Chronic Kidney Disease Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017–2030
The findings from the National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center (NIDDK) suggests that the overall prevalence of CKD increased from 12 percent to 14 percent between 1988 and 1994 and from 1999 to 2004 but has remained relatively stable since 2004.
Similarly, the National Kidney Foundation states that CKD affects an estimated 37 million people in the U.S. (15% of the adult population; more than 1 in 7 adults) and approximately 90% of those with CKD do not even know they have it. Centers for Disease Control and Prevention (CDC) highlights that not all patients with kidney disease progress to kidney failure.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook